TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6359109
Drug: Labetalol (non‐cardioselective,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (non‐cardioselective, alpha‐blocker)
Study: 28490560
Drug: Team-care deprescribing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Team-care deprescribing practice using a deprescribing guide (Beers and STOPP criteria, drug interaction checking)
Study: 23034965
Drug: Long-chain n-3
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-chain n-3 PUFAs (3.36 g/d)
Study: 17963164
Drug: Continue GC
Normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue GC treatment
Study: 17963164
Drug: Withdraw GC
Normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdraw GC treatment
Study: 15167190
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (patients managed by internal medicine residents before the addition of a second physician)
Study: 1809445
Drug: Dexamethasone 1
Normalized name: dexamethasone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 1 mg each night for 4 weeks
Study: 6308754
Drug: Mecillinam (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecillinam (200 mg daily for 25 days)
Study: 23748920
Drug: apixaban 2.5
Normalized name: apixaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: apixaban 2.5 mg BID
Study: 23748920
Drug: apixaban 5
Normalized name: apixaban 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: apixaban 5 mg BID
Study: 17939152
Drug: Test product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product (huperzine A 0.2 mg)
Study: 17939152
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product (huperzine A 0.2 mg)
Study: 29394348
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg/day for 4 weeks
Study: 26725583
Drug: Nefopam 20
Normalized name: nefopam 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam 20 mg intravenous (i.v.) 30 min before surgery, followed by an i.v. infusion (5 mg/h) for 24 h
Study: 10525564
Drug: Oral L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-arginine (50 mg/kg body weight)
Study: 8381932
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II (ANGII) infusion after pretreatment with lithium 750 mg
Study: 3113242
Drug: Misoprostol (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (800 micrograms in two or four divided doses daily)
Study: 29202887
Drug: 100-KGM (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-KGM (no pasta and all KGM-gel, 322 kJ (77 kcal))
Study: 29202887
Drug: 50-KGM (half
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-KGM (half pasta and half KGM-gel, 1084 kJ (259 kcal))
Study: 21988614
Drug: FT (new
Approvals — FDA: no, EMA: no, PMDA: no
Description: FT (new prefilled insulin pen)
Study: 19583931
Drug: Xuesaitong Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuesaitong Injection (400 mg in 250 mL 5% glucose injection, administered once daily for 6 days post-operation)
Study: 19583931
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional anti-infection and transfusion treatment)
Study: 11359221
Drug: Regional block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional block with 18 mL of 1% ropivacaine and oral mexiletine for the first 6 postoperative days (R + M group)
Study: 10636072
Drug: High-dose combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose combined hepatitis A and B vaccine (720 E1.U HAV antigen; 20 microg HBsAg)
Study: 8635828
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg vitamin K intramuscularly
Study: 8635828
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg vitamin K orally
Study: 8635828
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin K
Study: 8635828
Drug: Intramuscular vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vitamin K
Study: 2697625
Drug: Inhaled terbutaline
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled terbutaline 0.5 mg via a spacer
Study: 24714530
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment group received a single treatment of 15 minutes of sham ultrasound after the marathon run
Study: 17854995
Drug: Oral sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose (25%; 0.5 ml/kg)
Study: 16005496
Drug: Dexamethasone 3
Normalized name: dexamethasone 3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 3 mg twice daily for 5 days
Study: 10787444
Drug: Baseline diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline diet (BL) - 39% kcal fat, 164 mg cholesterol/1000 kcal
Study: 313245
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant high-dose methotrexate with leucovorin rescue
Study: 17239066
Drug: Acupressure treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure treatment for 4 weeks, 15 minutes, twice a day, five days a week.
Study: 17239066
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (companionship and conversation) for 4 weeks after a treatment-free period.
Study: 11965102
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy and radiotherapy for good responders
Study: 11965102
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy and radiotherapy for good responders with fixed arytenoid
Study: 11965102
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy and radiotherapy for good responders with non-fixed arytenoid
Study: 11965102
Drug: Arytenoid mobility
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arytenoid mobility before treatment
Study: 7707457
Drug: 12.5 mg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg/min erythromycin
Study: 22275463
Drug: Conventional arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional arm therapy
Study: 20040895
Drug: Single Morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Morning Dosage (SMD) NaHCO3
Study: 20040895
Drug: Single Evening
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single Evening Dosage (SED) NaHCO3
Study: 20040895
Drug: Consecutive Evening
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Consecutive Evening Dosage (CED) NaHCO3
Study: 10419079
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and Placebo (combined)
Study: 2145347
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic factor (ANF) infusion (0.1 microgram/kg/min during 30 minutes)
Study: 2145347
Drug: Salbutamol infusion
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol infusion (0.13 microgram/kg/min)
Study: 27761582
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg bolus followed by 75 mg daily
Study: 27761582
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg daily (no bolus)
Study: 24169063
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate aqueous nasal spray (MFNS) at 200 micrograms
Study: 19517198
Drug: Nitroglycerine ointment
Normalized name: nitroglycerin Rectal Ointment
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerine ointment (GTN)
Study: 19517198
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of botulinum toxin (BTX)
Study: 18007569
Drug: Oral ziprasidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ziprasidone (20 mg) after an 8-hour fast
Study: 18007569
Drug: Oral ziprasidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ziprasidone (40 mg) after an 8-hour fast
Study: 18007569
Drug: Oral ziprasidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ziprasidone (80 mg) after an 8-hour fast
Study: 18007569
Drug: Oral ziprasidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ziprasidone (40 mg) with a high-fat meal (60% fat)
Study: 18007569
Drug: Oral ziprasidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ziprasidone (40 mg) with a moderate-fat meal (30% fat)
Study: 18007569
Drug: Oral ziprasidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ziprasidone (40 mg) under fasting conditions
Study: 9041947
Drug: L-arginine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (8 gm/day for 28 days)
Study: 3216031
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg controlled-release tablet every 8 hours with cimetidine 300 mg four times a day for 7 days
Study: 3216031
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg controlled-release tablet every 8 hours without cimetidine
Study: 3216031
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg controlled-release tablet every 8 hours with cimetidine
Study: 31931853
Drug: Guhong injection
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guhong injection
Study: 28874596
Drug: Panax ginseng
Normalized name: Panax Ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panax ginseng extract (PG) 400 mg twice daily for 28 days
Study: 18443313
Drug: Hydrocortisone 40
Normalized name: hydrocortisone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 40 mg IV
Study: 10344353
Drug: Theophylline (810
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (810 mg daily)
Study: 9180981
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (RL, n = 10)
Study: 1919149
Drug: Cimetidine, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 50 mg/kg administered intravenously immediately before IPHP
Study: 29880243
Drug: Tdap administered
Normalized name: acellular pertussis vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap administered 3-4 weeks before MCV4 and PCV13
Study: 29880243
Drug: Tdap administered
Normalized name: acellular pertussis vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap administered concomitantly with MCV4 and PCV13
Study: 29880243
Drug: MCV4 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCV4 and PCV13 administered 3-4 weeks before Tdap
Study: 27498916
Drug: Budesonide (by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (by face mask inhalation or aerosol inhaler)
Study: 16846547
Drug: Micronized purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized purified flavonoid fraction (MPFF), six tablets per day for 4 days followed by four tablets per day for 3 days
Study: 12744364
Drug: Intravenous vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous vancomycin (2 g/day, four infusions/day)
Study: 12744364
Drug: Intraventricular vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraventricular vancomycin (10 mg once daily)
Study: 11168190
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of implants (EG)
Study: 8997652
Drug: Salifluor combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salifluor combined with PVM/MA copolymer and NaF in mouthrinse and dentifrice formulations.
Study: 1443440
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium supplementation for 6 weeks
Study: 29562659
Drug: Three energy
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three energy drinks (EDs) consumed at one-hour intervals (240 mg of caffeine total)
Study: 12017407
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (insulin LP)
Study: 12017407
Drug: Insulin R
Normalized name: insulin regular
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin R
Study: 10394005
Drug: First-line treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line treatment with monotherapy on an outpatient basis
Study: 7580637
Drug: Intensive diabetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive diabetic therapy
Study: 7580637
Drug: Conventional diabetic
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional diabetic therapy
Study: 6766731
Drug: acebutolol 200
Normalized name: acebutolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: acebutolol 200 mg twice daily
Study: 6766731
Drug: acebutolol 400
Normalized name: acebutolol 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: acebutolol 400 mg once daily
Study: 27647784
Drug: Haemodynamic-guided heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemodynamic-guided heart failure management (Treatment group)
Study: 26281946
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (manual therapies including desensitization maneuvers), n = 60
Study: 17122108
Drug: Lutein supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein supplementation (10 mg/d for 6 months)
Study: 8285950
Drug: propofol in
Normalized name: propofol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol in combination with ketamine 20 mg
Study: 8285950
Drug: propofol in
Normalized name: propofol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol in combination with fentanyl 0.1 mg
Study: 8285950
Drug: thiopentone in
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: thiopentone in combination with fentanyl 0.1 mg
Study: 8285950
Drug: methohexitone in
Normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: methohexitone in combination with fentanyl 0.1 mg
Study: 30303626
Drug: Nemiralisib (200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemiralisib (200, 500, and 700 μg)
Study: 27025777
Drug: Subcutaneous drainage
Normalized name: PLEURX DRAINAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous drainage (DG)
Study: 19268926
Drug: Assisted hatching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assisted hatching performed by acidic Tyrode's solution
Study: 17301956
Drug: Intravenous carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous carboplatin (18.7 mg/kg for patients < 12 kg, 560 mg/m(2) for patients >/= 12 kg)
Study: 9732929
Drug: Sodium picosulphate
Normalized name: Sodium Picosulfate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium picosulphate plus magnesium citrate (SPS‐Mg)
Study: 2972162
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg 17 beta‐estradiol cyclo‐octyl acetate (E2COA) + 0.15 mg desogestrel
Study: 2972162
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg micronized 17 beta‐estradiol (mE2) + 0.15 mg desogestrel
Study: 17429754
Drug: Accelerated protocol
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated protocol (progressive doses of Dobutamine with early atropine administration)
Study: 17429754
Drug: Conventional protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional protocol (progressive doses of Dobutamine with late atropine administration)
Study: 1494189
Drug: No injections
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injections (Group III, Control)
Study: 26002807
Drug: Other prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other prescription methods (primarily oral contraceptives)
Study: 23103177
Drug: High-dose rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rifampicin (600 mg, about 13 mg/kg) intravenously
Study: 23103177
Drug: Standard-dose rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose rifampicin (450 mg, about 10 mg/kg) orally
Study: 23103177
Drug: Moxifloxacin 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 800 mg once daily
Study: 23103177
Drug: Ethambutol 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethambutol 750 mg once daily
Study: 23103177
Drug: Standard-dose isoniazid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose isoniazid, pyrazinamide, and adjunctive corticosteroids
Study: 16682586
Drug: Macular grid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macular grid laser photocoagulation after intravitreal injection of 4 mg of triamcinolone acetonide (IVTA)
Study: 16682586
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of 4 mg of triamcinolone acetonide (IVTA) only
Study: 9387944
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (400 mg x day(-1))
Study: 3669768
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose CVP (cyclophosphamide 1500 mg/m2 i.v. day 1, vincristine 1.4 mg/m2 day 1, and prednisone 40 mg/m2 orally days 1‐10)
Study: 3669768
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose CAVP (cyclophosphamide 1000 mg/m2 i.v. day 1, doxorubicin 45 mg/m2 i.v. day 1, vincristine and prednisone as above)
Study: 3669768
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose CAVP
Study: 3669768
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose CVP and CAVP
Study: 29307683
Drug: Sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg regularly twice per week for 3 months immediately after urethral catheter removal
Study: 29307683
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment with sildenafil starting 3 months after surgery
Study: 21423852
Drug: MTZ 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTZ 500 mg twice a day for 7 days
Study: 21423852
Drug: MTZ 2-gm
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTZ 2-gm single dose
Study: 18278532
Drug: Best supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best supportive therapy (control)
Study: 16271721
Drug: Intravenous ergometrine
Normalized name: Ergometrine
DrugBank: Ergometrine (DB01253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ergometrine
Study: 8894357
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg b.i.d. for 4 weeks (patients with PUD)
Study: 8894357
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg b.i.d. for 4 weeks (patients without PUD)
Study: 1814841
Drug: Ofloxacin 50
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 50 mg
Study: 1814841
Drug: Ofloxacin 50
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 50 to 200 mg
Study: 28864706
Drug: Escalating with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating with reset contingency management (CM) as an adjunct to standard smoking cessation treatment over a 5-week period
Study: 26530856
Drug: Preventive interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive interventions (surgery, embolization, radiation therapy, alone or combined)
Study: 20137481
Drug: Venlafaxine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine treatment for 8 weeks
Study: 9070591
Drug: TPM 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPM 1,000 mg/day
Study: 9070591
Drug: TPM 100
Normalized name: TPM
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TPM 100 mg/day
Study: 8444274
Drug: Jejunal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Jejunal infusion of 1.3 kcal min‐1 (5.5 kJ min‐1)
Study: 8444274
Drug: Jejunal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Jejunal infusion of 3.3 kcal min‐1 (14.0 kJ min‐1)
Study: 3098132
Drug: 2% nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% nitroglycerin ointment applied to the forehead 12 minutes prior to intubation
Study: 3098132
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no nitroglycerin ointment)
Study: 30453487
Drug: Test yogurt
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test yogurt enriched with Lactococcus lactis 11/19-B1 and Bifidobacterium lactis BB-12, 80 g daily for 8 weeks